Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Spotlight Article

Next steps in targeting the CNS with AAV-driven gene therapy

Trends and advances in gene therapy delivery and gene editing

Bruce Goldsmith

BRUCE GOLDSMITH is Passage Bio’s CEO and President, and he also serves on its Board of Directors. Dr Goldsmith has extensive experience in the biopharma and biotechnology industries through the many roles he has held across the research and corporate spectrum. Prior to Passage, Dr Goldsmith was a Venture Partner at Deerfield Ventures and Interim CEO of Civetta Therapeutics.

DOI: 10.18609/cgti.2020.067 Q Can
Citation: Cell & Gene Therapy Insights 2020; 6(4), 577–582
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog